(ER) and progesterone receptor (PR), with the aim of the study being to provide robust confirmatory evidence on known associations in these biomarkers and to uncover new data on previously undescribed or unconfirmed biomarkers, thus strengthening the evidence‐base in clinical breast cancer testing....
Breast cancer is the leading type of cancer in terms of number of cases and rapid increase in the number of newly diagnosed breast cancer is observed during the past few years. Besides the availability of various breast cancer targeting therapeutic agents, the mortality rate is increasing at an ...
Results The classifiers were able to distinguish normal tissue from breast cancer with a classification performance of AUC = 0.82 ± 0.04 with the proteins MIF, MMP-9, and MPO. The classifiers distinguished normal tissue from benign lesions similarly at AUC = 0.80 ± 0.05. However, the serum ...
The overexpression of human epidermal growth factor receptor-2 (HER2) results in a biologically and clinically aggressive breast cancer (BC) subtype. Since the introduction of anti-HER2 targeted agents, survival rates of patients with HER2-positive metastatic BC have dramatically improved. Currently, ...
While results of CA27.29 tests are generally concordant with those of CA15-3 tests, they should not be interpreted interchangeably. Thymidine kinase – particularly its isozyme thymidine kinase 1 – is another key biomarker for breast cancer. As a newer and less well-studied biomarker, TK1 ...
Tiffany Traina, MD, discusses the body of evidence supporting the use of CDK4/6 inhibitors in hormone receptor–positive, HER2-negative breast cancer, shifting standards of care in HER2-positive disease, as well as biomarkers of response with checkpoint inhibitors and PARP inhibitors in triple-neg...
Breast Cancer Biomarkers Not every breast cancer treatment works equally well for every person. That’s because everyone’s body and everyone’s cancer is different. Your doctor can get clues as to how your cancer may behave by looking at what are called biomarkers. ...
Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the...
2. Meric-Bernstam F, Johnson A, Holla V, et al: A decision support framework for genomically informed investigational cancer therapy.J Natl Cancer Inst 107:djv098, 2015. 3. André F, Ciruelos EM, Rubovszky G, et al: Alpelisib + fulvestrant for advanced...
Breast cancer is one of the most frequently diagnosed cancers among women in the western world. Due to the aggressive behaviour of some specific types and the possibility of an early diagnosis, breast cancer has been constantly studied. Tumour size, hist